Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models
Abhik Bandyopadhyay, Long Wang, Joseph Agyin et al. · 2010
Read Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models by Abhik Bandyopadhyay, Long Wang, Joseph Agyin et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010365.txt.
Description
Abhik Bandyopadhyay and colleagues combined two cancer drugs in mouse breast tumors for PLOS ONE in 2010. A change in tumor cells, called EMT, can make cancers spread and resist drugs. A signal protein named TGF-beta strongly drives that change. The team paired a standard drug, doxorubicin, with a small compound that blocks TGF-beta. They tested the pair in mouse models of metastatic breast cancer.
Blocking the signal aimed to stop tumor cells from gaining stem-like traits. Those traits are tied to relapse after treatment. The drug pair thus attacks both the tumor bulk and its hardest cells. Mouse success is only a first step toward human use. Still, the logic of pairing a killer drug with an anti-spread drug is clearly laid out.
Catalog record
| CREATOR | Abhik Bandyopadhyay, Long Wang, Joseph Agyin et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010365